Until recently, CAR-T has been limited to niche haematological indications, and it is just about to break into the multiple myeloma space with its disproportionately wider patient population. As mentioned above, this strains hospital infrastructures and complicates supply chains, while also posing a new challenge for manufacturers in terms of commercial access. How can pharma convince community physicians to break away from the standard of care and experiment with such innovative treatments? How can physicians ensure that patients are correctly referred to CoE centres and their experience seamlessly managed? What is the role of patient and physician education in ensuring high quality follow ups? In the second of our three-part series on CAR-T therapies, we speak to Professor Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, about the current challenges of CAR-T access trying to capture both oncologists and patients’ perspectives.
